Table 1 The characteristics of 405 subjects with PM or malignant skin lesions divided into 12 groups according to skin lesion combinations
From: Spectrum of malignant and premalignant skin lesions in 505 adult subjects at risk of skin cancers
No skin cancer, no PM n = 100 | PM only n = 108 (AK 107, BD + AK 1) | BCC only n = 65 | SCC only n = 1 | MM only n = 48 (40 MM, 8 LM/MIS) | SCC + PM n = 10 (AK 9, BD + AK 1) | BCC + PM n = 102 (AK 99, BD + AK 3) | MM + PM n = 21 (MM 16, LM/MIS 5, AK 20, BD + AK 1) | MM + BCC n = 9 (MM 9, LM/MIS 0) | MM + SCC + PM n = 4 (MM 4, LM/MIS 0) | MM + BCC + PM n = 15 (MM 14, LM/MIS 1) | BCC + SCC + PM n = 17 (AK 15, BD + AK 2) | MM + BCC + SCC + PM n = 5 (MM 3, LM/MIS 2, AK 4, BD + AK 1) | P-value | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Proportion in 505 subjects | 19.8% | 21.4% | 12.9% | 0.2% | 9.5% | 2.0% | 20.2% | 4.2% | 1.8% | 0.8% | 3.0% | 3.4% | 1.0% | - |
Proportion in 405 subjects with PM and/or skin cancers | excluded | 26.7% | 16.0% | 0.2% | 11.9% | 2.5% | 25.2% | 5.2% | 2.2% | 1.0% | 3.7% | 4.2% | 1.2% | |
Age, years (n = 505) | ||||||||||||||
range | 21-75 | 43-79 | 31-79 | 27-73 | 58-79 | 40-79 | 57-79 | 44-79 | 69-77 | 52-79 | 63-78 | 67-76 | < 0.001 | |
mean ± SD | 47.1 ± 14.0 | 67.6 ± 7.8 | 61.4±12.9 | 67.5 | 56.1±11.1 | 72.4±5.8 | 69.9±7.0 | 69.1±7.2 | 66.6±11.3 | 72.6±3.4 | 70.2±7.5 | 71.7±4.8 | 72.1±4.5 | |
Sex(n=505) | ||||||||||||||
Male (%) | 45 (45.0) | 59 (54.6) | 23 (35.4) | 0 (0.0) | 23 (47.9) | 6 (60.0) | 59 (57.8) | 10 (47.6) | 5 (55.6) | 3 (75.0) | 8 (53.3) | 11 (64.7) | 4 (80.0) | 0.204 |
Female | 55 | 49 | 42 | 1 | 25 | 4 | 43 | 11 | 4 | 1 | 7 | 6 | 1 | |
Immunosuppression n = 505) | ||||||||||||||
No | 63 | 90 | 56 | 1 | 45 | 8 | 87 | 16 | 9 | 4 | 14 | 12 | 4 | 0.406 |
Yes (%) | 37 (37.0) | 18 (16.7) | 9 (13.8) | 0 (0.0) | 3 (6.3) | 2 (20.0) | 15 (14.7) | 5 (23.8) | 0 (0.0) | 0 (0,.0) | 1 (6.7) | 5 (29.4) | 1 (20.0) | |
Organ transplant recipients, n (%) | 22 (22.0) | 5 (4.6) | 3 (4.6) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 5 (4.9) | 1 (4.8) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 2 (11.8) | 1 (20.0) | 0.456 |
PAASI score (mean±SD)(n = 503) | 30.5±31.4 | 78.4±36.4 | 53.0±31.7 | 90.0 | 56.6±38.4 | 95.3±55.6 | 85.0±39.6 | 78.6±36.9 | 82.4±48.8 | 104.3±87.9 | 92.9±31.9 | 104.1±67.3 | 91.8±42.7 | <0.001 |
Fitzpatrick skin type (n = 475) | ||||||||||||||
I | 3 | 5 | 1 | 0 | 3 | 0 | 6 | 1 | 1 | 0 | 4 | 0 | 0 | 0.103 |
II | 41 | 36 | 27 | 1 | 21 | 5 | 40 | 10 | 3 | 1 | 4 | 9 | 2 | |
III | 50 | 57 | 30 | 0 | 19 | 2 | 48 | 9 | 4 | 1 | 7 | 3 | 1 | |
IV | 2 | 5 | 2 | 0 | 2 | 0 | 3 | 1 | 0 | 2 | 0 | 2 | 1 | |
Number of AKs (n = 504) (%) | ||||||||||||||
0 | 100 (100) | 18 (16.8) | 65 (100.0) | 1 (100) | 48 (100) | 1 (10.0) | 26 (25.5) | 6 (28.6) | 9 (100) | 0 (0.0) | 3 (20.0) | 3 (17.6) | 2 (40.0) | < 0.001 |
1–3 | 0 (0.0) | 46 (43.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 5 (50.0) | 42 (41.2) | 10 (47.6) | 0 (0.0) | 1 (25.0) | 8 (53.3) | 5 (29.4) | 0 (0.0) | |
4–10 | 0 (0.0) | 27 (25.2) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 2 (20.0) | 21 (20.6) | 3 (14.3) | 0 (0.0) | 2 (50.0) | 1 (6.7) | 5 (29.4) | 2 (40.0) | |
over 10 | 0 (0.0) | 16 (15.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 2 (20.0) | 13 (12.7) | 2 (9.5) | 0 (0.0) | 1 (25.0) | 3 (20.0) | 4 (23.5) | 1 (20.0) | |
Number of moles (n = 503) (%) | ||||||||||||||
0–20 | 29 (29.0) | 73 (67.6) | 33 (50.8) | 1 (100) | 8 (16.7) | 9 (90.0) | 58 (57.4) | 11 (52.4) | 2 (22.2) | 2 (50.0) | 8 (52.2) | 10 (62.5) | 0 (0.0) | < 0.001 |
21–50 | 21 (21.0) | 20 (18.5) | 13 (20.0) | 0 (0.0) | 18 (37.5) | 0 (0.0) | 30 (29.7) | 3 (14.3) | 3 (33.3) | 1 (25.0) | 5 (33.3) | 2 (12.5) | 2 (40.0) | |
21–50 | 25 (25.0) | 8 (7.4) | 13 (20.0) | 0 (0.0) | 12 (25.0) | 1 (10.0) | 8 (7.9) | 5 (23.8) | 2 (22.2) | 0 (0.0) | 1 (6.7) | 3 (18.8) | 2 (40.0) | |
51–100 | 25 (25.0) | 7 (6.5) | 6 (9.2) | 0 (0.0) | 10 (20.8) | 0 (0.0) | 5 (5.0) | 2 (9.5) | 2 (22.2) | 1 (25.0) | 1 (6.7) | 1 (6.3) | 1 (20.0) | |